Skip to main content
. 2017 Oct 19;80(6):1171–1178. doi: 10.1007/s00280-017-3463-x

Fig. 4.

Fig. 4

Kaplan–Meier plot of progression free survival (weeks) in a pooled analysis of both renal cell carcinoma and soft tissue sarcoma patients with an average Cmin above (n = 51, solid line) or below (n = 10, dashed line) the exposure target of > 20 mg/L. Median progression free survival was 25.0 weeks for patients with high and 8.80 weeks for patients with low exposure, p = 0.012 (log-rank test)